RegenETP Dirección

Dirección controles de criterios 4/4

El CEO de RegenETP's es Richard Hague , nombrado en Apr 2020, tiene una permanencia de menos de un año. compensación anual total es $479.81K, compuesta por 93.5% salario y 6.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.62% de las acciones de la empresa, por valor de $902.39. La antigüedad media del equipo directivo y de la junta directiva es de 4.9 años y 6.8 años, respectivamente.

Información clave

Richard Hague

Chief Executive Officer (CEO)

US$479.8k

Compensación total

Porcentaje del salario del CEO	93.5%
Permanencia del CEO	4.2yrs
Participación del CEO	0.6%
Permanencia media de la dirección	5yrs
Promedio de permanencia en la Junta Directiva	7yrs

Actualizaciones recientes de la dirección

Recent updates

PolarityTE shares surge 25% after Diabetic Foot Ulcer trial met primary and secondary endpoint

May 10

What You Need To Know About PolarityTE, Inc.'s (NASDAQ:PTE) Investor Composition

Feb 19

PolarityTE to raise up to $10M with at-the-market offering

Jan 12

PolarityTE under pressure on pricing $8M registered direct offering

Dec 22

PolarityTE perks up after securing first U.S. patent

Nov 30

PolarityTE EPS beats by $0.02, beats on revenue

Nov 09

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Richard Hague en comparación con los beneficios de RegenETP?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2023	n/a	n/a	-US$8m
Dec 31 2022	US$480k	US$449k	-US$8m
Sep 30 2022	n/a	n/a	-US$16m
Jun 30 2022	n/a	n/a	-US$13m
Mar 31 2022	n/a	n/a	-US$17m
Dec 31 2021	US$1m	US$359k	-US$30m
Sep 30 2021	n/a	n/a	-US$32m
Jun 30 2021	n/a	n/a	-US$38m
Mar 31 2021	n/a	n/a	-US$47m
Dec 31 2020	US$996k	US$358k	-US$43m
Sep 30 2020	n/a	n/a	-US$54m
Jun 30 2020	n/a	n/a	-US$70m
Mar 31 2020	n/a	n/a	-US$80m
Dec 31 2019	US$2m	US$273k	-US$92m

Compensación vs. Mercado: La compensación total ($USD479.81K) de Richard está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD677.87K).

Compensación vs. Ingresos: La compensación de Richard ha sido consistente con los resultados de la empresa en el último año.

CEO

Richard Hague (64 yo)

4.2yrs

Permanencia

US$479,808

Compensación

Mr. Richard Hague is Director of Remedium Bio, Inc since 2022. He serves as President at PolarityTE, Inc. since August 2019 and its Chief Executive Officer since August 2021 and also served as its Chief Op...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Richard Hague	President	4.2yrs	US$479.81k	0.62% $ 6.3k
Nikolai Sopko	Chief Scientific Officer and VP of R&D	5.9yrs	sin datos	sin datos
Rich Haerle	Vice President of Investor Relations & Strategy	6.1yrs	sin datos	sin datos
Mark Lehman	Chief Legal Officer	no data	sin datos	sin datos
Angela Ziegler	Vice President of Marketing & Public Relations	no data	sin datos	sin datos
Alain Adam	Vice President of Sales	5.9yrs	sin datos	sin datos
Jon Anthony Burrows	Senior VP of Corporate Development & President of Contract Services	no data	sin datos	sin datos
Ryan Mathis	Chief Medical Officer	2.8yrs	sin datos	sin datos
Kolby Day	Senior Vice President of Manufacturing Operations	1.6yrs	sin datos	sin datos

5.0yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de RGTP.Q es experimentado (5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Richard Hague	President	less than a year	US$479.81k	0.62% $ 6.3k
Michael Callahan	Member of Clinical Advisory board	no data	sin datos	sin datos
Stephen Milner	Member of Clinical Advisory Board	7.5yrs	sin datos	sin datos
Michael Grant	Member of Clinical Advisory Board	7.5yrs	sin datos	sin datos
Anand Kumar	Member of Clinical Advisory Board	7.5yrs	sin datos	sin datos
Anthony Tufaro	Member of Clinical Advisory Board	no data	sin datos	sin datos
Trinity Bivalacqua	Member of Clinical Advisory Board	no data	sin datos	sin datos
Shannath Merbs	Member of Clinical Advisory Board	no data	sin datos	sin datos
Ryan Katz	Member of Clinical Advisory Board	no data	sin datos	sin datos
Martin Robson	Member of Clinical Advisory Board	7yrs	sin datos	sin datos
William Hickerson	Member of Clinical Advisory Board	7yrs	sin datos	sin datos
Jeffrey Shupp	Member of Clinical Advisory Board	7yrs	sin datos	sin datos

7.0yrs

Permanencia media

Junta con experiencia: La junta directiva de RGTP.Q se considera experimentada (6.8 años de antigüedad promedio).

RegenETP Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer

Polarityte, Inc. Appoints Jeff Dyer as A Member of the Board of Directors

Insufficient new directors

PolarityTE, Inc. Announces Resignation of Jeff Dyer from its Board of Directors

Independent Chairman of the Board recently bought US$259k worth of stock

Recent updates

RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLC

PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer

PolarityTE, Inc. announced delayed 10-Q filing

PolarityTE, Inc. Files Form 15

Nasdaq to Delist the Common Stock of PolarityTE

PolarityTE, Inc.(OTCPK:PTEI.Q) dropped from NASDAQ Composite Index

New major risk - Share price stability

PolarityTE's Common Stock To Be Delisted From Nasdaq

First quarter 2023 earnings released: US$0.58 loss per share (vs US$1.12 loss in 1Q 2022)

Full year 2022 earnings: EPS misses analyst expectations

Polarityte, Inc. Appoints Jeff Dyer as A Member of the Board of Directors

Insufficient new directors

Forecast to breakeven in 2025

Consensus forecasts updated

Price target decreased to US$1.25

Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)

Michael Brauser submitted a non-binding offer to acquire the remaining stake in PolarityTE, Inc. (NasdaqCM:PTE).

PolarityTE, Inc. Receives Deficiency Letter the Listing Qualifications Department of Nasdaq

PolarityTE, Inc. Announces Resignation of Jeff Dyer from its Board of Directors

Consensus revenue estimates fall by 40%

Price target decreased to US$15.38

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

PolarityTE down 10% on lower-than-expected Q2 revenue

PolarityTE, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Consensus forecasts updated

Price target decreased to US$15.38

First quarter 2022 earnings: Revenues miss analyst expectations

PolarityTE, Inc. Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE(R)

PolarityTE, Inc. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to US$1.08

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Will PolarityTE (NASDAQ:PTE) Spend Its Cash Wisely?

PolarityTE, Inc. Announces Results from Multi-Center Randomized Controlled Trial Evaluating Treatment of Venous Leg Ulcers with Its Investigational Product SkinTE plus standard of care vs SOC alone

PolarityTE, Inc. Announces Allowance of Fourth U.S. Patent

PolarityTE, Inc Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication

PolarityTE, Inc. Announces Submission of Complete Response to Fda's Clinical Hold Correspondence for Skinte® Investigational New Drug Application

Here's Why We're Watching PolarityTE's (NASDAQ:PTE) Cash Burn Situation

Third quarter 2021 earnings released: US$0.013 loss per share (vs US$0.18 loss in 3Q 2020)

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Filed Against PolarityTE, Inc

Independent Director Minnie Baylor-Henry has left the company

PolarityTE Provides Update on U.S. FDA Investigational New Drug Application for SkinTE®

Consensus forecasts updated

PolarityTE Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Second quarter 2021 earnings released: US$0.04 loss per share (vs US$0.33 loss in 2Q 2020)

PolarityTE Is Not A DeFi Coin

Does PolarityTE (NASDAQ:PTE) Have A Healthy Balance Sheet?

Independent Chairman of the Board recently bought US$259k worth of stock

First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.40 loss in 1Q 2020)

PolarityTE, Inc. Updates on SkinTE Biologic License Application

PolarityTE Announces Diabetic Foot Ulcer Trial Met Primary and Secondary Endpoint

PolarityTE shares surge 25% after Diabetic Foot Ulcer trial met primary and secondary endpoint

PolarityTE, Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021

What You Need To Know About PolarityTE, Inc.'s (NASDAQ:PTE) Investor Composition

Analysts update estimates

PolarityTE, Inc. Announces Submission of an Investigational New Drug Application

New 90-day high: US$1.54

PolarityTE Announces Completion of Target Enrollment in Diabetic Foot Ulcer Trial

PolarityTE, Inc. has completed a Follow-on Equity Offering in the amount of $10.000001 million.

PolarityTE to raise up to $10M with at-the-market offering

New 90-day high: US$1.32

PolarityTE under pressure on pricing $8M registered direct offering

New 90-day low: US$0.63

PolarityTE perks up after securing first U.S. patent

Polarityte Announces Dismissal of Securities Class Action Complaint with Prejudice

Revenue beats expectations, earnings disappoint

Third quarter 2020 earnings released: US$0.18 loss per share

New 90-day low: US$0.81